

EXOMIND: Binge Eating

Novel ExoTMS Technology for the Reduction of Binge Eating Symptoms: Multicenter Review

David Pánek, MD, PhD¹, Toni Slavchev Donchev, MD²


1. DP Neuro, Czechia, 2. Assoc. Professor, Medical Center Intermedica, Bulgaria

Highlights

- 38 patients (24-66 years, BMI 19.6-44.4 kg/m²) with binge eating symptoms received 6 ExoTMS sessions
- Patients were evaluated using the validated Binge Eating Scale (BES) questionnaire
- 92% of patients reported therapies as comfortable; no adverse events were reported



Patients showed a complete
alleviation of binge eating
symptoms at 1-month follow-up



Patients reported improvement
of self-control over eating at
1-month follow-up




Figure 1: The BES questionnaire measures binge eating severity on a scale of 0-46: <17 = no binge eating, 18-26 = moderate binge eating, and ≥27 = severe binge eating. At baseline, all patients exhibited binge eating symptoms. At 1-month follow-up, 28 subjects (74%) showed no binge eating behavior.